Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The clinical effectiveness of parenterally-administered glucagon-like peptide-1 (GLP-1) mimetics to improve glucose control in patients suffering from type 2 diabetes strongly supports discovery pursuits aimed at identifying and developing orally active, small molecule GLP-1 receptor agonists. The purpose of these studies was to identify and characterize novel nonpeptide agonists of the GLP-1 receptor. RESEARCH DESIGN AND METHODS: Screening using cells expressing the GLP-1 receptor and insulin secretion assays with rodent and human islets were used to identify novel molecules. The intravenous glucose tolerance test (IVGTT) and hyperglycemic clamp characterized the insulinotropic effects of compounds in vivo. RESULTS: Novel low molecular weight pyrimidine-based compounds that activate the GLP-1 receptor and stimulate glucose-dependent insulin secretion are described. These molecules induce GLP-1 receptor-mediated cAMP signaling in HEK293 cells expressing the GLP-1 receptor and increase insulin secretion from rodent islets in a dose-dependent manner. The compounds activate GLP-1 receptor signaling, both alone or in an additive fashion when combined with the endogenous GLP-1 peptide; however, these agonists do not compete with radiolabeled GLP-1 in receptor-binding assays. In vivo studies using the IVGTT and the hyperglycemic clamp in Sprague Dawley rats demonstrate increased insulin secretion in compound-treated animals. Further, perifusion assays with human islets isolated from a donor with type 2 diabetes show near-normalization of insulin secretion upon compound treatment. CONCLUSIONS: These studies characterize the insulinotropic effects of an early-stage, small molecule GLP-1 receptor agonist and provide compelling evidence to support pharmaceutical optimization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One study showed that compound B almost normalised insulin secretion in human islets isolated from a T2D donor.286”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [286]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Structural diversity of G protein-coupled receptors and significance for drug discovery
Lagerström, M. C., & Schiöth, H. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2518 · Cited by 1,492
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · cited 1×
“In addition, these therapies often reduce body weight and improve several cardiovascular parameters (5,6).”
BackgroundVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884 · cited 1×
“Impairment of the incretin effect, including reduced secretion of glucagonlike peptide-1 (GLP-1) (1,2), is implicated in the progression of pancreatic islet dysfunction in type 2 diabetic patients.”
BackgroundMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882 · cited 2×
“GLP-1 is a glucose-dependent insulinotropic peptide (27,28).”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · cited 1×
“Impairment of the incretin effect, including reduced secretion of glucagonlike peptide-1 (GLP-1) (1,2), is implicated in the progression of pancreatic islet dysfunction in type 2 diabetic patients.”
BackgroundGöke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 2×
“B: The competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.”
BackgroundMethodKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 1×
“In addition, these therapies often reduce body weight and improve several cardiovascular parameters (5,6).”
BackgroundAllosteric Modulation of G Protein–Coupled Receptors
May, L. T., Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105159 · Cited by 695
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615 · cited 2×
“GLP-1 is a glucose-dependent insulinotropic peptide (27,28).”
Background
Cited by
Items 101–146 of 146
Thapa, B., Suh, E. H., Parrott, D., Khalighinejad, P., Sharma, G., Chirayil, S., & Sherry, A. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.809867 · Cited by 13
“5 g/kg glucose in fasted Sprague Dawly (SD) rats (44).”
MethodTechnology combination to address GPCR allosteric modulator drug-discovery pitfalls
Schann, S., Bouvier, M., & Neuville, P. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.09.008 · Cited by 13
Miller, M. M., & DelMonte, A. J. (2011) · Progress in heterocyclic chemistry · doi:10.1016/b978-0-08-096805-6.00013-9 · Cited by 14
2‐Sulfonylpyrimidines Target the Kinesin HSET via Cysteine Alkylation
Förster, T., Shang, E., Shimizu, K., Sanada, E., Schölermann, B., Huebecker, M., Hahne, G., López‐Alberca, M. P., Janning, P., Watanabe, N., et al. (2019) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201900586 · Cited by 12
Dengler, D. G., Sun, Q. Y., Holleran, J. P., Pollari, S., Beutel, J., Brown, B. T., Iwaya, A. S., Ardecky, R., Harikumar, K. G., Miller, L. J., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220945284 · Cited by 13
A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists
Yamazaki, K., Kagaya, T., Watanabe, M., Terauchi, H., Daisuke, I. I. D. A., FUKUMOTO, H., Suzuki, S., Tohru, A. R. A. I., Aoki, M., Takase, K., et al. (2013) · Biomedical Research · doi:10.2220/biomedres.34.129 · Cited by 10
“also found pyrimidine derivatives of GLP-1R agonists (23).”
BackgroundMoon, H.-S., Kim, M.-K., & Son, M.-H. (2011) · Archives of Pharmacal Research · doi:10.1007/s12272-011-0721-z · Cited by 9
Franklin, Z. J., McDonnell, B. M., Montgomery, I. A., Flatt, P. R., & Irwin, N. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01401.x · Cited by 10
Underwood, C. R., Knudsen, S. M., Wulff, B. S., Bräuner‐Osborne, H., Lau, J. F., Knudsen, L. B., Peters, G. H. J., & Reedtz‐Runge, S. (2011) · Pharmacology · doi:10.1159/000334338 · Cited by 9
Ibetazol, a novel inhibitor of importin β1-mediated nuclear import
Vercruysse, T., Vanstreels, E., Jacquemyn, M., Boland, S., Kilonda, A., Allasia, S., Vandecaetsbeek, I., Klaassen, H., Versele, M., Chaltin, P., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-07237-8 · Cited by 13
“Of note, a molecule with a chemical structure similar to ibetazol, BETP, was previously described as a glucagon-like peptide-1 receptor (GLP-1R) agonist 18,19 .”
A quinoxaline-based compound ameliorates bone loss in ovariectomized mice
Zhou, Y. J., Xue, X., Guo, Y., Liu, H., Hou, Z., Zhou, C., Wang, N., Li, F., & Wang, Y. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211032133 · Cited by 10
“In vivo, administration of DMB to mice in combination with glucose could significantly minimize the overall glycemic excursion.(24,25) However, it is not clear whether DMB has similar effects on bone metabolism.”
BackgroundAnother milestone in the evolution of GLP-1-based diabetes therapies
Nauck, M. A., Quast, D. R., & Meier, J. J. (2021) · Nature Medicine · doi:10.1038/s41591-021-01394-7 · Cited by 7
Allosteric modulators targeting GPCRs
López-Rodríguez, M. L., Benhamú, B., & Vázquez‐Villa, H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816228-6.00011-8 · Cited by 10
Chou, I.-W., Cheng, R. Y.-H., Chen, Y., Hsieh, P. C. H., & King, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12290-x · Cited by 7
Kang, S., Kim, N. H., & Yu, Y. G. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.10.071 · Cited by 6
Abbas, G., Haq, Q. M. I., Hamaed, A. M., Al-Sibani, M., & Hussain, H. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200131143231 · Cited by 6
Prolonged Activation of the GLP-1 Receptor via Covalent Capture
Ünsal, Ö., Bacaksiz, Z. S., Khamraev, V., Montanari, V., Beinborn, M., & Kumar, K. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00039 · Cited by 5
Plant-derived coumarins: emerging natural scaffolds for antidiabetic drug discovery
Attri, S. M., Sahu, S. K., & Kaur, P. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11474-w · Cited by 3
“GLP-1R agonists, SGLT2 inhibitors, and DPP-4 inhibitors are examples of more recent therapies [ 5, 6].”
Reed, J., Higginbotham, V., Bain, S. C., & Kanamarlapudi, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126331 · Cited by 3
“Interestingly, the allosteric agonists have also been shown to act as ago-allosteric modulators of GLP-1R by enhancing GLP-1 binding to the GLP-1R and acting in an additive manner to increase GSIS [17,18].”
BackgroundMethodQuintilhano, D. L., Miksza, D. R., Galia, W. B. D. S., Ramalho, M. O. R. C., Lucena, C. F., Valle, M. M. R., Graciano, M. F. R., de Souza, H. M., & Bertolini, G. L. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-02006-w · Cited by 3
Zhu, F., Castillo-Quan, J. I., Ogawa, T., Wu, Z., Ding, L., Sura, M., Watanabe, Y., Lentschat, H., Fernández-Cárdenas, L. P., Dag, U., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2530979123 · Cited by 2
“N - tert - butylaminoquinoxaline (referred to as “Compound 2”), an ago - allosteric modulator of the GLP - 1R that can both act as an agonist on its own and also enhance the effects of natural ligand GLP - 1 (42) in C. elegans .”
New technologies enabling the industrialization of allosteric modulator discovery
Lütjens, R., Perry, B., Schelshorn, D. W., & Rocher, J. (2013) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2013.01.001 · Cited by 2
Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07
Han, J. D. J., Sun, L., Qian, H., & Huang, W. (2014) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(14)60093-5 · Cited by 2
AlNeyadi, S. S., Adem, A., Amer, N., Salem, A. A., & Abdou, I. M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.032 · Cited by 2
Song, L., Barrett, D. G., Cox, K. L., Efanov, A. M., Syed, S. K., Tomandl, D., & Willard, F. S. (2020) · Assay and Drug Development Technologies · doi:10.1089/adt.2020.1011 · Cited by 2
Self-citationNew drugs for the treatment of diabetes mellitus
Bailey, C. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch47 · Cited by 3
In silico prediction of GLP-1R agonists using machine learning approach
Kuang, Z., Cheng, X., Yang, Z., Guo, Y.-X., Huang, Y., & Su, Z. (2021) · Chemical Papers · doi:10.1007/s11696-021-01600-3 · Cited by 2
Thamaraiselvan, V., & Ravichandiran, V. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1835720 · Cited by 1
“Following are the reasons for their selection (Coopman et al., 2010; Graaf et al., 2016; Irwin et al., 2010; Sloop et al., 2010; Wootten et al., 2013), (1) Total 29 compounds were available with their activity data (EC50) (2) Compound-2 (also called compound-16f) acts as an ago-allosteric…”
BackgroundActivation of the GLP-1 receptor by chloropyrimidine derivatives
AlNeyadi, S. S., Adem, A., Amer, N., Ghattas, M. A., Atatreh, N., Salem, A. A., & Abdou, I. M. (2021) · Results in Chemistry · doi:10.1016/j.rechem.2021.100222 · Cited by 2
The activation of the glucagon-like peptide-1 (GLP-1) receptor by peptide and non-peptide ligands
Wishart, C. (2013) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Mohr, K., & Kostenis, E. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1583
Wootten, D. L., Savage, E. E., Valant, C., May, L. T., Sloop, K. W., FICORILLI, J. V., Showalter, A. D., Willard, F. S., Christopoulos, A., & Sexton, P. M. (2012)
Self-citationMerchant, C. E. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0105089
The preproglucagon derived peptides and energy homeostasis
Parker, J. (2013) · doi:10.25560/10956
Nolte, W. M., & Carpino, P. A. (2016) · Royal Society of Chemistry eBooks · doi:10.1039/9781782629276-00271
Wootten, D. L., Savage, E. E., Willard, F. S., Bueno, A. B., Sloop, K. W., Christopoulos, A., & Sexton, P. M. (2013)
Self-citationGlucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Potential in antidiabetic and antioxidant therapies
Hameed, S., Khan, K. M., & Solangi, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15650-2.00007-6
Lead-guided prodrug development of small molecules as GLP-1R agonists
Lentschat, H., Aboelfotouh, H. G., Nabil, P., Abdallah, M., Khalifa, H., Stichel, J., Abdel‐Halim, M., Abadi, A. H., & Beck‐Sickinger, A. G. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110210 · Cited by 1
G-protein-coupled receptors (GPCRs) in the treatment of diabetes
Abirami, P. M., & Ramkumar, K. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33887-8.00018-0
BindingDB Entry 50022117: Binding sites and design strategies for small molecule GLP-1R agonists.
BindingDB (2025) · UC San Diego · doi:10.7270/q2474gk6
Signalling and Regulation of the Glucagon-like Peptide-1 receptor
Lu, J. N. (2014) · Figshare
Metadata
- Authors
- Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., Gutierrez Sanfeliciano, S. M., Tebbe, M. J., & Coghlan, M. J.
- Affiliations
- Eli Lilly (United States) (US)
- Discovery Chemistry Research and Technologies, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
- Corresponding author
- Sloop, Kyle W.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-09-07
- Volume
- 59
- Issue
- 12
- Pages
- 3099-3107
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2992771
- OpenAlex
- W2142458050
- Cited by
- 143
- References
- 35
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 14 · 2020: 12 · 2019: 8 · 2018: 3 · 2017: 7 · 2016: 10 · 2015: 10 · 2014: 17 · 2013: 19 · 2012: 12
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor agonists, small molecule agonists, insulin secretion, type 2 diabetes, pyrimidine derivatives, cAMP signaling, glucose-dependent insulin secretion, human pancreatic islets, oral GLP-1 receptor agonists, drug discovery
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Cyclic AMP, Animals, Gastric Inhibitory Polypeptide, Glucagon, Glucose Tolerance Test, Humans, Insulin, Islets of Langerhans, Luciferases, Male, Parathyroid Hormone, Vasoactive Intestinal Peptide, Rats, Sprague-Dawley, Genes, Reporter, Receptors, Glucagon, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.